Fast Learn

  • Johnson & Johnson (JNJ) generates over $115 yearly in passive revenue from a $5,000 funding.

  • JNJ has raised its dividend for 64 consecutive years with a 2.39% indicated yield.

  • The analyst who referred to as NVIDIA in 2010 simply named his prime 10 shares and Johnson & Johnson wasn’t one in all them. Get them right here FREE.

Passive revenue is the money move that arrives whether or not you’re working, sleeping, or watching the market churn. For traders who’ve spent many years constructing a paycheck, the enchantment of a portfolio that pays you on a hard and fast schedule is much less about getting wealthy and extra about getting dependable. Earned revenue stops the second you do. Dividend revenue doesn’t.

Healthcare and client staples have lengthy anchored revenue portfolios as a result of their money flows are largely insensitive to recession threat. The trade-off with a blue-chip identify is yield: you hand over the double-digit headline fee of a mortgage REIT or a BDC in trade for a verify that has not been reduce, suspended, or skipped in dwelling reminiscence. For traders who need quarterly reliability over yield maximization, that commerce is the whole level.

We screened our 24/7 Wall St. dividend fairness analysis database, searching for shares that pay sturdy, rising dividends, and we discovered a Dividend King that may generate over $115 a 12 months in passive annual revenue in the event you make investments simply $5,000 in it on the time of this writing.

The analyst who referred to as NVIDIA in 2010 simply named his prime 10 shares and Johnson & Johnson wasn’t one in all them. Get them right here FREE.

Johnson & Johnson

  • Yield: 2.26% (indicated ahead yield nearer to 2.39% on the brand new $1.34 quarterly fee)

  • Shares for $5,000: 22.3 at $224.20

  • Annual Passive Revenue: $119.54 (about $29.88 each quarter)

Johnson & Johnson (NYSE:JNJ) is a diversified world healthcare firm that operates two reporting segments after the Kenvue spin: Progressive Drugs (prescription drugs) and MedTech (medical gadgets). Six precedence franchises, oncology, immunology, neuroscience, cardiovascular, surgical procedure, and imaginative and prescient, drove $96.4 billion in trailing-twelve-month income and an working margin of 27.4%.

Q1 2026 income rose 9.9% YoY, led by DARZALEX, TREMFYA, CARVYKTI, and a MedTech cardiovascular enterprise absorbing the STELARA biosimilar erosion with out breaking stride.

JHVEPhoto / iStock Editorial through Getty Photos

Dividend Aristocrat at a Low cost

The dividend yield trails REIT and BDC requirements, however the payout is engineered for permanence. JNJ is without doubt one of the few U.S. firms carrying a chief AAA credit standing, and administration has now raised the payout for 64 consecutive years.

The latest hike, introduced April 14, lifted the quarterly dividend from $1.30 to $1.34, with a Might 26, 2026 ex-dividend date and a June 9, 2026 cost date. Annualized, that’s $5.36 per share, up from $4.96 in 2024 and $4.45 in 2022. The money to fund these raises comes from a steadiness sheet that produced $19.7 billion in free money move final 12 months.

Possession is overwhelmingly institutional at 76.2% of the float, with Vanguard, BlackRock, and State Road the most important holders, the usual possession profile of a Dow Jones Industrial Common element. Current company exercise has been deliberate: a $1 billion-plus funding in next-generation cell remedy manufacturing in Pennsylvania, the closing of the Intra-Mobile Therapies acquisition that added CAPLYTA, the Halda Therapeutics deal in oral most cancers degraders, and a deliberate separation of the DePuy Synthes orthopaedics enterprise inside 18 to 24 months.

Administration has additionally raised FY2026 steerage to $100.3 billion to $101.3 billion in income and adjusted EPS of $11.45 to $11.65. CEO Joaquin Duato instructed traders JNJ “had a robust begin to 2026 and is delivering on its promise for a 12 months of accelerated progress and influence.”

The Backside Line

A $5,000 stake in JNJ at $224.20 buys roughly 22.3 shares and produces about $119.54 a 12 months in dividends, deposited in 4 checks of roughly $29.88. That could be a 2.39% indicated yield on a inventory that has returned 47.59% over the previous 12 months and 161.73% over the previous decade on a worth foundation alone.

The argument for a reputation like JNJ inside a passive revenue technique rests on the understanding of the subsequent 64 checks. Reinvested by way of a DRIP, that $119.54 stream compounds into incrementally bigger payouts each quarter as each share depend and dividend per share develop. For revenue traders who measure success in years, not weeks, that quiet accumulation is the whole job.

The analyst who referred to as NVIDIA in 2010 simply named his prime 10 AI shares

This analyst’s 2025 picks are up 106% on common. He simply named his prime 10 shares to purchase in 2026. Get them right here FREE.

https://weblog.passive-income4u.com/create-your-very-own-auto-publish-news-blog-site-and-earn-passive-income-in-just-4-easy-steps/

LEAVE A REPLY

Please enter your comment!
Please enter your name here